Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 26, 2026

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

View original at globenewswire.com
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Prolaris + AI test is the only test where active surveillance metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.

    60% confidence

  • AI-GUR is a statistically significant predictor of Gleason upgrade at first follow-up biopsy, independent of time elapsed since diagnosis and other clinical variables, and provides information not captured by conventional risk stratification tools or cribriform morphology.

    60% confidence

  • The predictive power of AI-GUR is robust across biopsy intervals, suggesting it may capture both disease progression and mischaracterization of the initial biopsy.

    60% confidence

  • The Prolaris Biopsy Test has already outperformed other biomarker tests in identifying appropriate patients for active surveillance in low and intermediate-risk populations.

    60% confidence

  • PATHOMIQ's AI image-based approach can deliver results within one day of receiving the digital images from the patient's biopsy or surgical sample.

    60% confidence

  • Prolaris + AI is the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.

    60% confidence

  • Prostate cancer is projected to be the leading cancer diagnosis in the U.S. in 2026, with more than 300,000 patients newly diagnosed. The Prolaris + AI Test introduces a valuable tool for active surveillance planning.

    60% confidence

  • The new AI metric will be available for all Prolaris Biopsy Tests performed on samples in the U.S. (other than from New York State) starting with tests processed on May 29, 2026. Approval for samples from New York State is expected to come soon.

    60% confidence

Cited in these Via News reports